Literature DB >> 28638734

Severe, but not mild heat-shock treatment induces immunogenic cell death in cancer cells.

Irena Adkins1,2, Lenka Sadilkova1, Nada Hradilova1,2, Jakub Tomala3, Marek Kovar3, Radek Spisek1,2.   

Abstract

The mechanisms of immunogenicity underlying mild heat-shock (mHS) treatment < 42°C of tumor cells are largely attributed to the action of heat-shock proteins; however, little is known about the immunogenicity of tumor cells undergoing severe cytotoxic heat-shock treatment (sHS > 43°C). Here, we found that sHS, but not mHS (42°C), induces immunogenic cell death in human cancer cell lines as defined by the induction of ER stress response and ROS generation, cell surface exposure of calreticulin, HSP70 and HSP90, decrease of cell surface CD47, release of ATP and HMGB1. Only sHS-treated tumor cells were efficiently killed and phagocytosed by dendritic cells (DCs), which was partially dependent on cell surface calreticulin. DCs loaded with mHS or sHS-treated tumor cells displayed similar level of maturation and stimulated IFNγ-producing CD8+ T cells without any additional adjuvants in vitro. However, only DCs loaded with sHS-treated tumor cells stimulated antigen-specific CD4+ T cells and induced higher CD8+ T-cell activation and proliferation. sHS-treated murine cells also exposed calreticulin, HSP70 and HSP90 and activated higher DC maturation than mHS treated cells. Vaccination with sHS-treated tumor cells elicited protective immunity in mice. In this study, we defined specific conditions for the sHS treatment of human lung and ovarian tumor cells to arrive at optimal ratio between effective cell death, immunogenicity and content of tumor antigens for immunotherapeutic vaccine generation.

Entities:  

Keywords:  Antitumor immunity; calreticulin; cancer immunotherapy; dendritic cells; heat-shock treatment; hyperthermia; immunogenic cell death

Year:  2017        PMID: 28638734      PMCID: PMC5467989          DOI: 10.1080/2162402X.2017.1311433

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN: 2162-4011            Impact factor:   8.110


  52 in total

1.  Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway.

Authors:  Taoyong Chen; Jun Guo; Chaofeng Han; Mingjin Yang; Xuetao Cao
Journal:  J Immunol       Date:  2009-02-01       Impact factor: 5.422

2.  A mechanism for the specific immunogenicity of heat shock protein-chaperoned peptides.

Authors:  R Suto; P K Srivastava
Journal:  Science       Date:  1995-09-15       Impact factor: 47.728

Review 3.  Cancer immunotherapy based on intracellular hyperthermia using magnetite nanoparticles: a novel concept of "heat-controlled necrosis" with heat shock protein expression.

Authors:  Akira Ito; Hiroyuki Honda; Takeshi Kobayashi
Journal:  Cancer Immunol Immunother       Date:  2005-08-25       Impact factor: 6.968

4.  The inducible Hsp70 as a marker of tumor immunogenicity.

Authors:  P R Clark; A Ménoret
Journal:  Cell Stress Chaperones       Date:  2001-04       Impact factor: 3.667

5.  Hyperthermia enhances CTL cross-priming.

Authors:  Hongzhen Shi; Tinghua Cao; John E Connolly; Laurence Monnet; Lynda Bennett; Sylvie Chapel; Claude Bagnis; Patrice Mannoni; Jean Davoust; A Karolina Palucka; Jacques Banchereau
Journal:  J Immunol       Date:  2006-02-15       Impact factor: 5.422

Review 6.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

Review 7.  Heat shock proteins transfer peptides during antigen processing and CTL priming.

Authors:  P K Srivastava; H Udono; N E Blachere; Z Li
Journal:  Immunogenetics       Date:  1994       Impact factor: 2.846

8.  Reduction of endoplasmic reticulum Ca2+ levels favors plasma membrane surface exposure of calreticulin.

Authors:  R Tufi; T Panaretakis; K Bianchi; A Criollo; B Fazi; F Di Sano; A Tesniere; O Kepp; P Paterlini-Brechot; L Zitvogel; M Piacentini; G Szabadkai; G Kroemer
Journal:  Cell Death Differ       Date:  2007-11-23       Impact factor: 15.828

Review 9.  Hyperthermia on immune regulation: a temperature's story.

Authors:  Hua-Gang Zhang; Keyur Mehta; Patrice Cohen; Chandan Guha
Journal:  Cancer Lett       Date:  2008-07-01       Impact factor: 8.679

10.  Bordetella adenylate cyclase toxin differentially modulates toll-like receptor-stimulated activation, migration and T cell stimulatory capacity of dendritic cells.

Authors:  Irena Adkins; Jana Kamanova; Aneta Kocourkova; Martina Svedova; Jakub Tomala; Hana Janova; Jiri Masin; Barbora Chladkova; Ladislav Bumba; Marek Kovar; Padraig J Ross; Ludmila Tuckova; Radek Spisek; Kingston H G Mills; Peter Sebo
Journal:  PLoS One       Date:  2014-08-01       Impact factor: 3.240

View more
  16 in total

1.  Trabectedin Reveals a Strategy of Immunomodulation in Chronic Lymphocytic Leukemia.

Authors:  Priyanka Banerjee; Ronghua Zhang; Cristina Ivan; Giovanni Galletti; Karen Clise-Dwyer; Federica Barbaglio; Lydia Scarfò; Miguel Aracil; Christian Klein; William Wierda; William Plunkett; Federico Caligaris-Cappio; Varsha Gandhi; Michael J Keating; Maria Teresa S Bertilaccio
Journal:  Cancer Immunol Res       Date:  2019-09-17       Impact factor: 11.151

Review 2.  Recent Progress in the Synergistic Combination of Nanoparticle-Mediated Hyperthermia and Immunotherapy for Treatment of Cancer.

Authors:  Zachary R Stephen; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2020-11-25       Impact factor: 9.933

3.  "UPRegulation" of CD47 by the endoplasmic reticulum stress pathway controls anti-tumor immune responses.

Authors:  Katherine L Cook; David R Soto-Pantoja
Journal:  Biomark Res       Date:  2017-08-14

4.  Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion.

Authors:  Sander Bekeschus; Ramona Clemen; Felix Nießner; Sanjeev Kumar Sagwal; Eric Freund; Anke Schmidt
Journal:  Adv Sci (Weinh)       Date:  2020-03-30       Impact factor: 16.806

5.  Image-Guided Radiofrequency Hyperthermia (RFH)-Enhanced Direct Chemotherapy of Hepatic Tumors: The Underlying Biomolecular Mechanisms.

Authors:  Kun Qian; Minjiang Chen; Feng Zhang; Jeffrey Forris Beecham Chick; Hongxiu Ji; Chuansheng Zheng; Xiaoming Yang
Journal:  Front Oncol       Date:  2021-01-28       Impact factor: 6.244

6.  Differential Effect of Non-Thermal Plasma RONS on Two Human Leukemic Cell Populations.

Authors:  Hager Mohamed; Eric Gebski; Rufranshell Reyes; Samuel Beane; Brian Wigdahl; Fred C Krebs; Katharina Stapelmann; Vandana Miller
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

7.  Hmox1 Upregulation Is a Mutual Marker in Human Tumor Cells Exposed to Physical Plasma-Derived Oxidants.

Authors:  Sander Bekeschus; Eric Freund; Kristian Wende; Rajesh Kumar Gandhirajan; Anke Schmidt
Journal:  Antioxidants (Basel)       Date:  2018-10-27

8.  Anti-Metastatic Benefits Produced by Hyperthermia and a CCL3 Derivative.

Authors:  Liqiu Ma; Ryosuke Kambe; Tomoko Tsuchiya; Shiro Kanegasaki; Akihisa Takahashi
Journal:  Cancers (Basel)       Date:  2019-11-11       Impact factor: 6.639

Review 9.  Hyperthermia Targeting the Tumor Microenvironment Facilitates Immune Checkpoint Inhibitors.

Authors:  Zihui Li; Jie Deng; Jianhai Sun; Yanling Ma
Journal:  Front Immunol       Date:  2020-11-09       Impact factor: 7.561

Review 10.  Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Authors:  Lorenzo Galluzzi; Ilio Vitale; Sarah Warren; Sandy Adjemian; Patrizia Agostinis; Aitziber Buqué Martinez; Timothy A Chan; George Coukos; Sandra Demaria; Eric Deutsch; Dobrin Draganov; Richard L Edelson; Silvia C Formenti; Jitka Fucikova; Lucia Gabriele; Udo S Gaipl; Sofia R Gameiro; Abhishek D Garg; Encouse Golden; Jian Han; Kevin J Harrington; Akseli Hemminki; James W Hodge; Dewan Md Sakib Hossain; Tim Illidge; Michael Karin; Howard L Kaufman; Oliver Kepp; Guido Kroemer; Juan Jose Lasarte; Sherene Loi; Michael T Lotze; Gwenola Manic; Taha Merghoub; Alan A Melcher; Karen L Mossman; Felipe Prosper; Øystein Rekdal; Maria Rescigno; Chiara Riganti; Antonella Sistigu; Mark J Smyth; Radek Spisek; John Stagg; Bryan E Strauss; Daolin Tang; Kazuki Tatsuno; Stefaan W van Gool; Peter Vandenabeele; Takahiro Yamazaki; Dmitriy Zamarin; Laurence Zitvogel; Alessandra Cesano; Francesco M Marincola
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.